Cornelius Adebahr
{
"authors": [
"Cornelius Adebahr"
],
"type": "commentary",
"centerAffiliationAll": "dc",
"centers": [
"Carnegie Endowment for International Peace",
"Carnegie Europe"
],
"collections": [
"Iranian Proliferation"
],
"englishNewsletterAll": "",
"nonEnglishNewsletterAll": "",
"primaryCenter": "Carnegie Europe",
"programAffiliation": "EP",
"programs": [
"Europe"
],
"projects": [],
"regions": [
"North America",
"United States",
"Middle East",
"Iran",
"Western Europe"
],
"topics": [
"Nuclear Policy"
]
}Source: Getty
Europe Is Late but Crucial in U.S.-Iran Nuclear Talks
Despite a slow start, the EU is working hard to hammer out a renewed nuclear deal between the United States and Iran. But it won’t be easy.
Vienna, here we come—again. Six years after world powers concluded their negotiations on Iran’s nuclear program in the Austrian capital, diplomats are talking again in the stucco-clad ballrooms of otherwise mostly deserted five-star hotels. Yet despite the genteel setting, the talks will be no waltz in the park.
The EU is starting from a weaker position this time
The EU is trying to broker an agreement between the United States and Iran on each side’s return to the deal. Yet just like in July 2015, success is far from guaranteed. In fact, the Europeans look much weaker today than then, and that’s not just because of their dismal record in the ongoing coronavirus pandemic. If anything, the past three years since the United States left the Joint Comprehensive Plan of Action, or JCPOA, have shown Europe’s inability to keep the deal alive beyond its vital functions.
It’s true that France, Germany, and the UK—the three European co-signatories of the deal (the E3)—have fought hard to prevent the agreement from unravelling, including by torpedoing America’s unilateral efforts to reinstate all United Nations sanctions on Iran in September 2020. However, they could not maintain the economic opening that Tehran was promised in return for strict supervision of its nuclear program. Even after the pandemic had hit the Islamic Republic especially hard, European governments failed to find a way to increase humanitarian trade, or indeed grant multilateral aid to Iran, in the face of continuing U.S. sanctions.
Why a new deal will be hard to strike
The Europeans are learning the hard way that it is one thing to rally countries around the world against a bully in the White House but quite another to devise a plan for two sworn enemies with toxic domestic politics to find common ground again. In addition, they too have grown wary of an Iranian government that has methodically dismantled its compliance with the nuclear agreement, while enlarging its foothold in the wider region and violently cracking down on popular dissent at home.
In a similar way, U.S. President Joe Biden is realizing that although he promised to return to the deal on the campaign trail, it is hard to enact a compliance-for-compliance approach once in office. The previous administration had painstakingly built a “sanctions wall” against Iran to prevent a successor’s possible return to the JCPOA. Specifically, it went beyond just reinstating all nuclear-related sanctions by late 2018 and deliberately repackaged some of them as measures against Iran’s missile program and regional activities, in order to make the sanctions’ undoing prohibitively costly in political terms.
All this was clear when Biden won the U.S. vote in November 2020. Yet the Europeans missed the chance to prepare the ground for talks, when time was of essence. Since then, Iran has made significant advances on developing more capable centrifuges and enriching uranium to 20 percent—far above the level needed for a civilian nuclear energy program. The time it would take Iran to amass enough fissile material for one atomic bomb is now estimated to have shrunk from over a year to a couple of months.
Iran’s political calendar is also constraining the chances for compromise. Its presidential election is a mere ten weeks away, and it’s not clear how the coming campaign will influence the diplomatic dynamics. For sure, the incumbent, President Hassan Rouhani, would like to see his signature success—the lifting of international sanctions following the 2015 deal—vindicated by a renewed agreement. However, the country’s Supreme Leader, Ayatollah Ali Khamenei, has raised the bar for any bargain by asking for assurances that, this time, Washington will live up to its word. In addition, a hardliner-dominated parliament has issued guidance to drastically reduce international inspections, a move that has only been put on hold for a three-month window ending in late May, after the International Atomic Energy Agency scrambled to reach a temporary agreement.
Europe’s difficult tasks ahead
For Europe, the negotiations that have begun in Vienna this week are the last chance to save a deal that is essential to its security, as leaders have repeatedly claimed. Together with the Austrian government hosting the talks and the E3 representatives shuttling between the Americans and Iranians in their separate hotels, the EU—as chair of the JCPOA’s joint commission—is working on two to-do lists. The first is to spell out what Tehran needs to do to come back into compliance on the nuclear front. The second—likely much longer one—will set out precisely how Washington needs to cut back its sanctions architecture. Once this short-term return to the deal is secured, the parties can engage in the hard slog of curtailing Iran’s reach by setting up a regional security architecture.
Without Europe’s mediation efforts, any agreement in such a distrustful atmosphere will be elusive. Yet it took the Europeans far too long to step up their game and engage in this eleventh-hour diplomatic dance—in the very city of their lone foreign policy success of late.
About the Author
Former Nonresident Fellow, Carnegie Europe
Cornelius Adebahr was a nonresident fellow at Carnegie Europe. His research focuses on foreign and security policy, in particular regarding Iran and the Persian Gulf, on European and transatlantic affairs, and on citizens’ engagement.
- EU-Iran: Time to Revisit Assumptions and StrategizeCommentary
- Making an Inclusive EU Strategy on Iran a RealityResearch
Cornelius Adebahr, Barbara Mittelhammer
Recent Work
Carnegie India does not take institutional positions on public policy issues; the views represented herein are those of the author(s) and do not necessarily reflect the views of Carnegie, its staff, or its trustees.
More Work from Carnegie India
- The Impact of U.S. Sanctions and Tariffs on India’s Russian Oil ImportsCommentary
This piece examines India’s response to U.S. sanctions and tariffs, specifically assessing the immediate market consequences, such as alterations in import costs, and the broader strategic implications for India’s energy security and foreign policy orientation.
Vrinda Sahai
- NISAR Soars While India-U.S. Tariff Tensions SimmerCommentary
On July 30, 2025, the United States announced 25 percent tariffs on Indian goods. While diplomatic tensions simmered on the trade front, a cosmic calm prevailed at the Sriharikota launch range. Officials from NASA and ISRO were preparing to launch an engineering marvel into space—the NASA-ISRO Synthetic Aperture Radar (NISAR), marking a significant milestone in the India-U.S. bilateral partnership.
Tejas Bharadwaj
- TRUST and TariffsCommentary
The India-U.S. relationship currently appears buffeted between three “Ts”—TRUST, Tariffs, and Trump.
Arun K. Singh
- The India-U.S. TRUST Initiative: Advancing Semiconductor Supply Chain CooperationCommentary
As part of the TRUST initiative, leaders of the two countries committed to building trusted and resilient supply chains, including for semiconductors and critical minerals. India and the United States have made steady progress in this area over the years. This essay explores the takeaways from discussions on semiconductor supply chains that took place at Carnegie India’s 9th Global Technology Summit.
Konark Bhandari
- The India-U.S. TRUST Initiative: A Resilient Pharma Supply ChainCommentary
This essay takes stock of the early momentum generated by the joint leaders’ commitment to catalyze public and private investments in building Indian manufacturing capacity—both domestically and in the United States—for active pharmaceutical ingredients (APIs) for critical medicines.
Shruti Sharma